Information and recommendations for manufacturers on the preparation and presentation of a periodic safety update report (PSUR).
Similar Posts
Regulation of AI in Healthcare
The MHRA is seeking evidence on the regulation of AI in healthcare to inform the recommendations of the National Commission into the Regulation of AI in Healthcare.
Class 2 Medicines Recall: ChloraPrep 1mL Clear Sterile Solution/Applicator, Becton Dickinson UK Ltd, EL(25)A/36
Becton Dickinson UK Ltd has informed the MHRA that some units exhibit an open seal on the packaging of the applicator. This is linked to the Class 2 Medicines Notification EL(25)A/22. This defect could increase the risk of the applicator device being contaminated with pathogens.
Professor Alastair Denniston: The future regulation of AI in healthcare
Creating a framework that is safe, fast and trusted.
MHRA approves UK’s first new type of antibiotic for urinary tract infections in nearly 30 years
As with any medicine, the MHRA will keep the safety of gepotidacin under close review.
MHRA Chair welcomes re-appointment of three non-executive directors
Professor Anthony Harnden has congratulated the trio of Agency board members on the extension of their appointments.
Class 4 Medicines Defect Notification: Olmesartan medoxomil 10mg film-coated tablets, Jubilant Pharmaceuticals NV, EL(25)A/37
Jubilant Pharmaceuticals NV has informed the MHRA that the Patient Information leaflet (PIL) in the cartons for the batches listed in this notification include an outdated PIL.